Gonorrhea infection in women: Prevalence, effects, screening, and management

Cheryl K. Walker, Richard L Sweet

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Gonorrhea is a set of clinical conditions resulting from infection with the sexually-acquired bacterial pathogen Neisseria gonorrhoeae. Acquisition may involve multiple mucosal sites in the lower female genital tract, including the urethra, cervix, Bartholin's and Skene's glands, as well as the anorectal canal, pharynx, and conjunctivae. It may spread to the upper genital tract, uterine tubes, abdominal cavity, and other systemic sites. Gonorrhea is the second most commonly reported sexually-transmitted infection in the US and rates are higher among women than men. Women and infants are affected disproportionately by gonorrhea, because early infection may be asymptomatic and also because extension of infection is often associated with serious sequelae. Screening is critical for infection identification and the prevention or limitation of upper genital tract spread, and horizontal and vertical transmission. Routine genital screening is recommended annually for all sexually active women at risk for infection, including women aged < 25 years and older women with one or more of the following risks: a previous gonorrhea infection, the presence of other sexually transmitted diseases, new or multiple sex partners, inconsistent condom use, commercial sex work, drug use, or human immunodefciency virus infection with sexual activity or pregnancy. Pharyngeal gonococcal infections are common in adolescents, and direct culture screening is necessary to identify affected individuals. Nucleic acid amplification tests (NAATs) are considered the standard for screening and diagnosis. Although urine NAAT testing is most commonly used, there is growing support for vaginal swabs collected by providers or patients themselves. Resistance to all antibiotics currently recommended for the treatment of gonorrhea has been documented and complicates therapeutic strategies. The Centers for Disease Control and Prevention recommend treatment of gonorrhea with a single class of drugs, ie, the cephalosporins.

Original languageEnglish (US)
Pages (from-to)197-206
Number of pages10
JournalInternational Journal of Women's Health
Volume3
Issue number1
StatePublished - 2011

Fingerprint

Gonorrhea
Infection
Nucleic Acid Amplification Techniques
Sexually Transmitted Diseases
Bartholin's Glands
Sex Work
Fallopian Tubes
Abdominal Cavity
Neisseria gonorrhoeae
Sexual Partners
Conjunctiva
Condoms
Virus Diseases
Urethra
Cephalosporins
Centers for Disease Control and Prevention (U.S.)
Pharynx
Cervix Uteri
Sexual Behavior
Pharmaceutical Preparations

Keywords

  • Cephalosporins
  • Gonorrhea
  • Infection
  • Treatment
  • Women

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Maternity and Midwifery

Cite this

Gonorrhea infection in women : Prevalence, effects, screening, and management. / Walker, Cheryl K.; Sweet, Richard L.

In: International Journal of Women's Health, Vol. 3, No. 1, 2011, p. 197-206.

Research output: Contribution to journalArticle

@article{607b6fd45d75448587c0d4916d08906c,
title = "Gonorrhea infection in women: Prevalence, effects, screening, and management",
abstract = "Gonorrhea is a set of clinical conditions resulting from infection with the sexually-acquired bacterial pathogen Neisseria gonorrhoeae. Acquisition may involve multiple mucosal sites in the lower female genital tract, including the urethra, cervix, Bartholin's and Skene's glands, as well as the anorectal canal, pharynx, and conjunctivae. It may spread to the upper genital tract, uterine tubes, abdominal cavity, and other systemic sites. Gonorrhea is the second most commonly reported sexually-transmitted infection in the US and rates are higher among women than men. Women and infants are affected disproportionately by gonorrhea, because early infection may be asymptomatic and also because extension of infection is often associated with serious sequelae. Screening is critical for infection identification and the prevention or limitation of upper genital tract spread, and horizontal and vertical transmission. Routine genital screening is recommended annually for all sexually active women at risk for infection, including women aged < 25 years and older women with one or more of the following risks: a previous gonorrhea infection, the presence of other sexually transmitted diseases, new or multiple sex partners, inconsistent condom use, commercial sex work, drug use, or human immunodefciency virus infection with sexual activity or pregnancy. Pharyngeal gonococcal infections are common in adolescents, and direct culture screening is necessary to identify affected individuals. Nucleic acid amplification tests (NAATs) are considered the standard for screening and diagnosis. Although urine NAAT testing is most commonly used, there is growing support for vaginal swabs collected by providers or patients themselves. Resistance to all antibiotics currently recommended for the treatment of gonorrhea has been documented and complicates therapeutic strategies. The Centers for Disease Control and Prevention recommend treatment of gonorrhea with a single class of drugs, ie, the cephalosporins.",
keywords = "Cephalosporins, Gonorrhea, Infection, Treatment, Women",
author = "Walker, {Cheryl K.} and Sweet, {Richard L}",
year = "2011",
language = "English (US)",
volume = "3",
pages = "197--206",
journal = "International Journal of Women's Health",
issn = "1179-1411",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Gonorrhea infection in women

T2 - Prevalence, effects, screening, and management

AU - Walker, Cheryl K.

AU - Sweet, Richard L

PY - 2011

Y1 - 2011

N2 - Gonorrhea is a set of clinical conditions resulting from infection with the sexually-acquired bacterial pathogen Neisseria gonorrhoeae. Acquisition may involve multiple mucosal sites in the lower female genital tract, including the urethra, cervix, Bartholin's and Skene's glands, as well as the anorectal canal, pharynx, and conjunctivae. It may spread to the upper genital tract, uterine tubes, abdominal cavity, and other systemic sites. Gonorrhea is the second most commonly reported sexually-transmitted infection in the US and rates are higher among women than men. Women and infants are affected disproportionately by gonorrhea, because early infection may be asymptomatic and also because extension of infection is often associated with serious sequelae. Screening is critical for infection identification and the prevention or limitation of upper genital tract spread, and horizontal and vertical transmission. Routine genital screening is recommended annually for all sexually active women at risk for infection, including women aged < 25 years and older women with one or more of the following risks: a previous gonorrhea infection, the presence of other sexually transmitted diseases, new or multiple sex partners, inconsistent condom use, commercial sex work, drug use, or human immunodefciency virus infection with sexual activity or pregnancy. Pharyngeal gonococcal infections are common in adolescents, and direct culture screening is necessary to identify affected individuals. Nucleic acid amplification tests (NAATs) are considered the standard for screening and diagnosis. Although urine NAAT testing is most commonly used, there is growing support for vaginal swabs collected by providers or patients themselves. Resistance to all antibiotics currently recommended for the treatment of gonorrhea has been documented and complicates therapeutic strategies. The Centers for Disease Control and Prevention recommend treatment of gonorrhea with a single class of drugs, ie, the cephalosporins.

AB - Gonorrhea is a set of clinical conditions resulting from infection with the sexually-acquired bacterial pathogen Neisseria gonorrhoeae. Acquisition may involve multiple mucosal sites in the lower female genital tract, including the urethra, cervix, Bartholin's and Skene's glands, as well as the anorectal canal, pharynx, and conjunctivae. It may spread to the upper genital tract, uterine tubes, abdominal cavity, and other systemic sites. Gonorrhea is the second most commonly reported sexually-transmitted infection in the US and rates are higher among women than men. Women and infants are affected disproportionately by gonorrhea, because early infection may be asymptomatic and also because extension of infection is often associated with serious sequelae. Screening is critical for infection identification and the prevention or limitation of upper genital tract spread, and horizontal and vertical transmission. Routine genital screening is recommended annually for all sexually active women at risk for infection, including women aged < 25 years and older women with one or more of the following risks: a previous gonorrhea infection, the presence of other sexually transmitted diseases, new or multiple sex partners, inconsistent condom use, commercial sex work, drug use, or human immunodefciency virus infection with sexual activity or pregnancy. Pharyngeal gonococcal infections are common in adolescents, and direct culture screening is necessary to identify affected individuals. Nucleic acid amplification tests (NAATs) are considered the standard for screening and diagnosis. Although urine NAAT testing is most commonly used, there is growing support for vaginal swabs collected by providers or patients themselves. Resistance to all antibiotics currently recommended for the treatment of gonorrhea has been documented and complicates therapeutic strategies. The Centers for Disease Control and Prevention recommend treatment of gonorrhea with a single class of drugs, ie, the cephalosporins.

KW - Cephalosporins

KW - Gonorrhea

KW - Infection

KW - Treatment

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=84055182496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055182496&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84055182496

VL - 3

SP - 197

EP - 206

JO - International Journal of Women's Health

JF - International Journal of Women's Health

SN - 1179-1411

IS - 1

ER -